CagriSema vs Tirzepatide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CagriSema
CagriSema is Novo Nordisk's investigational fixed combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). By pairing two complementary appetite pathways, it produced roughly 20–23% weight loss in trials. It was filed with the FDA in December 2025 but is not yet approved — and notably missed non-inferiority against tirzepatide in a head-to-head study.
Full profileTirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. Approved as Mounjaro (type 2 diabetes) and Zepbound (obesity), it produces greater weight loss than any approved GLP-1 monotherapy in clinical trials.
Full profile| CagriSema | Tirzepatide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | Cagrilintide + Semaglutide, AM833 + semaglutide, amylin/GLP-1 combination | LY3298176, Mounjaro, Zepbound |
| Evidence | Investigational (in trials) | FDA-approved |
| Dosing range | 0.25mg–2.4mg mg, once weekly subcutaneous (each component 2.4mg at target) | 2.5mg–15mg mg, Once weekly subcutaneous injection |
| Administration | Subcutaneous injection (weekly) | Subcutaneous injection (abdomen, thigh, or upper arm) |
| Key side effects | Nausea (most common, dose-dependent), Vomiting, Diarrhea or constipation, Decreased appetite | Nausea (most common, especially during titration), Vomiting, Diarrhea, Constipation |
| Cited sources | 2 references | 4 references |
Key differences
- Evidence level differs: CagriSema is investigational (in trials), while Tirzepatide is fda-approved.
- Administration: CagriSema — Subcutaneous injection (weekly); Tirzepatide — Subcutaneous injection (abdomen, thigh, or upper arm).
- Frequency: CagriSema is typically once weekly subcutaneous (each component 2.4mg at target); Tirzepatide is Once weekly subcutaneous injection.
- Research depth: this profile cites 2 sources for CagriSema vs 4 for Tirzepatide.
How each works
CagriSema
CagriSema combines amylin-receptor agonism (cagrilintide — satiety and gastric emptying via the area postrema/hypothalamus) with GLP-1 agonism (semaglutide), two non-overlapping appetite mechanisms. The REDEFINE 1 and 2 trials supported a December 2025 FDA filing for weight management. However, the open-label REDEFINE-4 head-to-head trial showed 23.0% weight loss vs 25.5% for tirzepatide 15 mg, missing its primary non-inferiority endpoint. An FDA decision is expected in late 2026.
Tirzepatide
The SURMOUNT-1 trial (N=2539) demonstrated up to 22.5% mean body weight reduction over 72 weeks at the 15mg dose — the highest efficacy ever recorded for a pharmaceutical weight loss agent at time of publication. The dual mechanism leverages GIP's potentiation of insulin secretion and adipose tissue effects alongside GLP-1's appetite suppression and gastric motility slowing. Head-to-head data (SURMOUNT-5) shows tirzepatide outperforms semaglutide 2.4mg for weight loss.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.